However, BRQ has exhibited promising anti-cancer activity targeting DHODH, as recently elucidated in preclinical anti-cancer studies in AML [41] and neuroblastoma [49], leading to the establishment of an ongoing clinical trial (ClinicalTrials.gov identifier: NCT03760666) studying the effect and tolerability of BRQ against AML in adults. This evidence concerns the gene DHODH and neuroblastoma.